title: Advances in the therapy of Alzheimer's disease: targeting amyloid beta and tau and perspectives for the future.
abstract: Worldwide multidisciplinary translational research has led to a growing knowledge of the genetics and molecular pathogenesis of Alzheimer's disease (AD) indicating that pathophysiological brain alterations occur decades before clinical signs and symptoms of cognitive decline can be diagnosed. Consequently, therapeutic concepts and targets have been increasingly focused on early-stage illness before the onset of dementia; and distinct classes of compounds are now being tested in clinical trials. At present, there is a growing consensus that therapeutic progress in AD delaying disease progression would significantly decrease the expanding global burden. The evolving hypothesis- and evidence-based generation of new diagnostic research criteria for early-stage AD has positively impacted the development of clinical trial designs and the characterization of earlier and more specific target populations for trials in prodromal as well as in pre- and asymptomatic at-risk stages of AD.
authors.affiliation: AXA Research Fund and UPMC Chair, Paris, France.
authors.forename: Harald
authors.initials: H
authors.lastname: Hampel
authors.forename: Lon S
authors.initials: LS
authors.lastname: Schneider
authors.forename: Ezio
authors.initials: E
authors.lastname: Giacobini
authors.forename: Miia
authors.initials: M
authors.lastname: Kivipelto
authors.forename: Shireen
authors.initials: S
authors.lastname: Sindi
authors.forename: Bruno
authors.initials: B
authors.lastname: Dubois
authors.forename: Karl
authors.initials: K
authors.lastname: Broich
authors.forename: Robert
authors.initials: R
authors.lastname: Nisticò
authors.forename: Paul S
authors.initials: PS
authors.lastname: Aisen
authors.forename: Simone
authors.initials: S
authors.lastname: Lista
mesh_terms: D000544:Alzheimer Disease / Q000188:drug therapy*; D016229:Amyloid beta-Peptides / Q000187:drug effects* / Q000378:metabolism; D000818:Animals; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000379:methods / Q000639:trends*; D006801:Humans; D016875:tau Proteins / Q000187:drug effects* / Q000378:metabolism
chemical_list: D016229:Amyloid beta-Peptides; D014150:Antipsychotic Agents; D016875:tau Proteins
keywords: Alzheimer’s disease; amyloid beta immunotherapy; bapineuzumab; biological markers; clinical trials; prevention; randomized controlled trials • systems biology; solanezumab; tau immunotherapy